[ad_1] Updated Jan. 13, 2024 2:20 pm ET WEST DES MOINES, Iowa—For those who speculate about what Vivek Ramaswamy really wants out of his long-shot Republican presidential bid—perhaps a podcast…
Tag: Biotechnology Services
WSJ News Exclusive | Novartis Pursuit of Cytokinetics Cools
[ad_1] Updated Jan. 11, 2024 12:47 pm ET Novartis has backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug…
Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for $2 Billion
[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
WSJ News Exclusive | Novartis in Advanced Talks to Buy Cytokinetics
[ad_1] Updated Jan. 8, 2024 1:14 pm ET Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharmaceutical companies continue to snap up…
Merck to Buy Harpoon Therapeutics for $680 Million
[ad_1] Merck & Co.has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million. Merck on Monday said it will pay $23 a share in cash…
Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B
[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
Ecstasy-for-Medicine Advocate Raises $100 Million
[ad_1] The Multidisciplinary Association for Psychedelic Studies, a nonprofit leader in the pharmaceutical psychedelics industry, has raised more than $100 million in a Series A private stock sale. MAPS needed…
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
[ad_1] Updated Dec. 26, 2023 12:33 pm ET Drug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio…